Literature DB >> 18853997

A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio.

Shaohua Chen1, Youming Li, Shengjie Li, Chaohui Yu.   

Abstract

BACKGROUND AND AIM: This study analyzes the effect of the val227ala variant of the peroxisome proliferators-activated receptor-alpha (PPAR-alpha) on non-alcoholic fatty liver disease.
METHODS: 79 patients with NAFLD and 63 healthy counterparts were included in the study. Body mass index (BMI), hip, waist, waist-to-hip ratio (WHR), blood pressure (BP), the percentage of body fat, total protein, albumin, ALT, triglyceride, cholesterol, HDL and fasting blood glucose were assessed. The genotypes were analyzed using oligonucleotide microarray. Logistic model was used to perform the multi-factors synthetical analysis on the data obtained to screen the risk factors closely associated with Val227Ala polymorphism of PPAR-alpha gene.
RESULTS: There were 6.33% (5/79) subjects with CC/CT genotype (ala227ala and val227ala) and 93.67% (74/79) subjects with TT genotype (val227val) in patients with NAFLD, and there were 20.63% (13/63) with CC/CT genotype and 79.37% (50/63) subjects with TT genotype. The distribution of PPAR-alpha val227ala polymorphism between NAFLD and healty subjects was significant (p = 0.011). The level of weight, body mass index, hip circumference, waist circumference, waist-hip ratio, percentage of body fat, abdominal wall fat thickness in subjects with Val227Ala variant were significantly lower than that in Val227wide type. The results showed that waist circumference and WHR were related with the PPAR-alpha val227ala polymorphism.
CONCLUSION: PPAR-alpha val227ala polymorphism may be involved in the pathogenesis of NAFLD and play a protective role in obesity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18853997     DOI: 10.1111/j.1440-1746.2008.05523.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  27 in total

Review 1.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 2.  The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis.

Authors:  Mithun Sharma; Shasikala Mitnala; Ravi K Vishnubhotla; Rathin Mukherjee; Duvvur N Reddy; Padaki N Rao
Journal:  J Clin Exp Hepatol       Date:  2015-02-16

3.  Development of gene polymorphisms in meditators of nonalcoholic fatty liver disease.

Authors:  Chun Wang; Jianping Gong; Hao Wu
Journal:  Biomed Rep       Date:  2017-06-14

Review 4.  Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.

Authors:  Tyler J Severson; Siddesh Besur; Herbert L Bonkovsky
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

Review 5.  The genetic backgrounds in nonalcoholic fatty liver disease.

Authors:  Yuya Seko; Kanji Yamaguchi; Yoshito Itoh
Journal:  Clin J Gastroenterol       Date:  2018-02-28

Review 6.  Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease.

Authors:  Hisamitsu Miyaaki; Kazuhiko Nakao
Journal:  Clin J Gastroenterol       Date:  2017-03-13

Review 7.  Role of peroxisome proliferator-activated receptors gene polymorphisms in type 2 diabetes and metabolic syndrome.

Authors:  Chen Dong; Hui Zhou; Chong Shen; Lu-Gang Yu; Yi Ding; Yong-Hong Zhang; Zhi-Rong Guo
Journal:  World J Diabetes       Date:  2015-05-15

Review 8.  NAFLD in Asia--as common and important as in the West.

Authors:  Geoffrey C Farrell; Vincent Wai-Sun Wong; Shiv Chitturi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

9.  Peroxisome proliferator-activated receptor alpha target genes.

Authors:  Maryam Rakhshandehroo; Bianca Knoch; Michael Müller; Sander Kersten
Journal:  PPAR Res       Date:  2010-09-26       Impact factor: 4.964

10.  Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα.

Authors:  Yan Lu; Xing Liu; Yang Jiao; Xuelian Xiong; E Wang; Xiaolin Wang; Zhijian Zhang; Huijie Zhang; Lingling Pan; Youfei Guan; Dongsheng Cai; Guang Ning; Xiaoying Li
Journal:  J Clin Invest       Date:  2014-07-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.